Akebia Ther (AKBA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $131.67M
Last updated: Nov 17, 2026 at 11:04 AM ET
Akebia Ther (AKBA) Stock Forecast
Analysts expect Akebia Ther (AKBA) to earn -$0.16 per share in the fiscal year ending Dec 31, 2026, on revenue of $171.42M. Of 6 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 16.7% |
| Buy | 4 | 66.7% |
| Hold | 1 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 39.0%.
- Fiscal year ending Dec 31, 2026
- -$0.16
- EPS consensus, revenue $171.42M
- Fiscal year ending Dec 31, 2027
- -$0.33
- EPS consensus, revenue $104.56M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.16 | -$0.16 to -$0.16 | 1 | $171.42M | $166.50M to $175.10M | 5 |
| Dec 31, 2027 | -$0.33 | -$0.33 to -$0.33 | 1 | $104.56M | $75.30M to $140.81M | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.04 for the quarter ending Dec 31, 2026 to -$0.09 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.04 | -$0.07 to -$0.01 | 8 | $32.80M | $26.26M to $37.80M | 8 |
| Mar 31, 2027 | -$0.09 | -$0.09 to -$0.09 | 1 | $25.07M | $18.60M to $30.50M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.11.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.16 | -$0.16 | -$0.16 | -$0.16 | -$0.11 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.33 | -$0.36 | -$0.36 | -$0.36 | -$0.20 | N/A |
| Quarter ending Mar 31, 2027 | -$0.09 | -$0.10 | -$0.10 | -$0.10 | -$0.06 | N/A |
Frequently Asked Questions About AKBA
What is the AKBA stock forecast?
Consensus analyst estimates put Akebia Ther's EPS at -$0.16 for the fiscal year ending Dec 31, 2026, on revenue of $171.42M. The consensus rating from 6 analysts is Buy.
How do analysts rate AKBA stock?
Of 6 analysts covering Akebia Ther, 1 rates it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from AKBA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.16, with estimates from -$0.16 to -$0.16 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.33, with estimates from -$0.33 to -$0.33 from 1 analyst.
What revenue do analysts expect from Akebia Ther next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $171.42M, with estimates from $166.50M to $175.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $104.56M, with estimates from $75.30M to $140.81M.
How many analysts cover AKBA?
6 analysts rate Akebia Ther stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
AKBA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors